XCNQOVAT
Market cap789kUSD
Dec 20, Last price
0.03CAD
1Q
20.00%
IPO
-93.18%
Name
Ovation Science Inc
Chart & Performance
P/E
—
P/S
18.33
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.47%
Rev. gr., 5y
-8.47%
Revenues
62k
-55.17%
Net income
-813k
L+2.26%
CFO
-336k
L-49.91%
Profile
Ovation Science Inc. engages in the production of cannabis or hemp products in Canada, the United States, and Mexico. The company's Invisicare is a patented drug delivery technology for use in topical and transdermal skin care products containing hemp seed oil and cannabis under the Ovation and BASKiN brands. It offers cannabidiol infused health and wellness solutions under the Invibe MD name; skincare solutions under the ARLO CBD name; and hand sanitizers under the DermSafe name. The company holds sublicenses for cannabis based products; and Lighthouse for licensed dispensaries in the United States. Ovation Science Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 62 -55.17% | 138 -38.58% | 225 -70.01% | ||||
Cost of revenue | 489 | 516 | 1,046 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (427) | (378) | (821) | ||||
NOPBT Margin | |||||||
Operating Taxes | 1 | 16 | |||||
Tax Rate | |||||||
NOPAT | (427) | (379) | (837) | ||||
Net income | (813) 2.26% | (795) -67.00% | (2,410) 100.73% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 200 | 20 | |||||
BB yield | -18.85% | -2.72% | |||||
| Debt | |||||||
Debt current | 174 | 23 | |||||
Long-term debt | 18 | 18 | |||||
Deferred revenue | |||||||
Other long-term liabilities | (18) | ||||||
Net debt | 144 | 12 | (648) | ||||
| Cash flow | |||||||
Cash from operating activities | (336) | (671) | (886) | ||||
CAPEX | 3 | ||||||
Cash from investing activities | 1,158 | ||||||
Cash from financing activities | 356 | 47 | |||||
FCF | (10) | (279) | (68) | ||||
| Balance | |||||||
Cash | 49 | 29 | 648 | ||||
Long term investments | |||||||
Excess cash | 46 | 22 | 636 | ||||
Stockholders' equity | (652) | (83) | 706 | ||||
Invested Capital | 193 | 41 | 70 | ||||
ROIC | |||||||
ROCE | 92.99% | 903.52% | |||||
| EV | |||||||
Common stock shares outstanding | 30,321 | 29,375 | 29,375 | ||||
Price | 0.04 40.00% | 0.03 -58.33% | 0.06 -83.10% | ||||
Market cap | 1,061 44.51% | 734 -58.33% | 1,762 -81.38% | ||||
EV | 1,205 | 747 | 1,115 | ||||
EBITDA | (424) | (371) | (813) | ||||
EV/EBITDA | |||||||
Interest | 31 | 588 | |||||
Interest/NOPBT | |||||||